Glaucoma, Open-AnglePhase 2NCT01001195

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

A Phase 2 study testing AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075% and AGN-210669 ophthalmic solution, 0.05% in people with Glaucoma, Open-Angle and Ocular Hypertension, run by Allergan at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®). Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Glaucoma, Open-Angle, Ocular Hypertension
What is being tested?: AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075% and AGN-210669 ophthalmic solution, 0.05%
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 165 participants
Where: 1 siteUnited States
Study dates: Nov 2009to Apr 2010
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Ocular hypertension or primary open-angle glaucoma in each eye
Patient requires IOP lowering medication in each eye

Who cannot join

Ocular hyperemia or other ocular surface findings in either eye
Active ocular disease
Current or anticipated use of any topical ocular medication (including artificial tears) during the study
Intraocular surgery within past six months or unilateral cataract surgery.
Functionally significant visual field loss
Anticipated wearing of contact lenses during study
Use of other medications that affect IOP such as glaucoma treating medications, within 2 months of screening visit

Trial locations and contacts

1 site in 1 country.

United States1 site

Study site
Rochester, New York

Other trials in United States

About this study

This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Being tested: AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%
Medical subject headings: Glaucoma, Open-Angle, Ocular Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

AGN-210669 ophthalmic solution, 0.1%Drug
One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
AGN-210669 ophthalmic solution, 0.075%Drug
One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
AGN-210669 ophthalmic solution, 0.05%Drug
One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
bimatoprost ophthalmic solution 0.03%Drug
Also called LUMIGAN®
One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

Study groups in NCT01001195
Study group	Role	What they receive
AGN-210669 ophthalmic solution, 0.1%	Experimental	One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. Receives: Drug: AGN-210669 ophthalmic solution, 0.1%
AGN-210669 ophthalmic solution, 0.075%	Experimental	One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. Receives: Drug: AGN-210669 ophthalmic solution, 0.075%
AGN-210669 ophthalmic solution, 0.05%	Experimental	One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. Receives: Drug: AGN-210669 ophthalmic solution, 0.05%
bimatoprost ophthalmic solution 0.03%	Active comparator	One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29. Receives: Drug: bimatoprost ophthalmic solution 0.03%

What is being measured

The primary outcome is the main question the study is designed to answer.

Change From Baseline in Average Eye Intraocular Pressure (IOP)
IOP is a measurement of the fluid pressure inside the eye. The average of the 2 eyes is used for the analyses. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening).
Measured: Baseline, Day 29 Hour 0

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Nov 2009Apr 2010

First posted26 Oct 2009 (estimated)
Study startNov 2009
Primary completionApr 2010
Study completionApr 2010

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Glaucoma, Open-AngleStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Triple blind
Who is masked: Participant, Investigator, Outcomes assessor
Enrolment: 165 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01001195
Sponsor's protocol ID: 210669-010
Status last verified: Aug 2013
First submitted: 22 Oct 2009
Last updated: 18 Oct 2013
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Recruiting
The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).
Glaucoma Open-Angle Primary, Hypertension
RecruitingPhase 4
Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Open Angle Glaucoma (OAG), Glaucoma
RecruitingObservational study
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
Primary Open Angle Glaucoma
Active, not recruitingObservational study
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Primary Open Angle Glaucoma

All Glaucoma, Open-Angle trials

Study at a glance

From the registry record, last updated by the sponsor on 18 Oct 2013. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution
ClinicalTrials.gov ID: NCT01001195
Acronym / sponsor ID: 210669-010
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Phase: Phase 2
Study type: Interventional
Recruitment status: Completed
Enrolment: 165 participants (actual)
Lead sponsor: AllerganIndustry (pharma, biotech, devices)
Study start: Nov 2009
Primary completion: Apr 2010 (actual)
Study completion: Apr 2010 (actual)
First posted: 26 Oct 2009 (estimated)
Results: Posted 18 Oct 2013

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Triple blind (participant, investigator, outcomes assessor)
Number of arms: 4

Arm	Type	Receives
AGN-210669 ophthalmic solution, 0.1%	Experimental	Drug: AGN-210669 ophthalmic solution, 0.1%One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
AGN-210669 ophthalmic solution, 0.075%	Experimental	Drug: AGN-210669 ophthalmic solution, 0.075%One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
AGN-210669 ophthalmic solution, 0.05%	Experimental	Drug: AGN-210669 ophthalmic solution, 0.05%One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
bimatoprost ophthalmic solution 0.03%	Active comparator	Drug: bimatoprost ophthalmic solution 0.03%One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (2 listed)

Ocular hypertension or primary open-angle glaucoma in each eye
Patient requires IOP lowering medication in each eye

Key exclusion criteria (7 listed)

Ocular hyperemia or other ocular surface findings in either eye
Active ocular disease
Current or anticipated use of any topical ocular medication (including artificial tears) during the study
Intraocular surgery within past six months or unilateral cataract surgery.
Functionally significant visual field loss

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
AGN-210669 ophthalmic solution, 0.1%One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.	Drug	AGN-210669 ophthalmic solution, 0.1%
AGN-210669 ophthalmic solution, 0.075%One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.	Drug	AGN-210669 ophthalmic solution, 0.075%
AGN-210669 ophthalmic solution, 0.05%One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.	Drug	AGN-210669 ophthalmic solution, 0.05%
bimatoprost ophthalmic solution 0.03%Also: LUMIGAN®One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.	Drug	bimatoprost ophthalmic solution 0.03%

Primary outcome

Change From Baseline in Average Eye Intraocular Pressure (IOP)
Time frame: Baseline, Day 29 Hour 0
IOP is a measurement of the fluid pressure inside the eye. The average of the 2 eyes is used for the analyses. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening).

Results and safety

Results posted to the registry on 18 Oct 2013, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
AGN-210669 Ophthalmic Solution, 0.1%	39	37
AGN-210669 Ophthalmic Solution, 0.075%	41	39
AGN-210669 Ophthalmic Solution, 0.05%	44	44
Bimatoprost Ophthalmic Solution 0.03%	41	41

Primary outcome: Change From Baseline in Average Eye Intraocular Pressure (IOP)

Time frame: Baseline, Day 29 Hour 0. Mean (Standard Deviation). Unit: Millimeters of Mercury (mmHg)

Measure	AGN-210669 Ophthalmic Solution, 0.1% n = 39	AGN-210669 Ophthalmic Solution, 0.075% n = 41	AGN-210669 Ophthalmic Solution, 0.05% n = 44	Bimatoprost Ophthalmic Solution 0.03% n = 41
Baseline - Hour 0	25.88 (3.696)	25.18 (2.382)	25.39 (2.770)	25.73 (3.490)
Change from Baseline at Day 29 - Hour 0	-7.50 (4.219)	-7.65 (3.171)	-5.66 (3.082)	-8.57 (3.854)

Population analysed: Modified Intent to Treat: all randomized and treated patients who had at least a baseline visit and 1 postbaseline IOP evaluation

Adverse events

Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
AGN-210669 Ophthalmic Solution, 0.1%	1 of 39 (2.6%)	28 of 39 (71.8%)	Not reported
AGN-210669 Ophthalmic Solution, 0.075%	0 of 41 (0%)	35 of 41 (85.4%)	Not reported
AGN-210669 Ophthalmic Solution, 0.05%	0 of 44 (0%)	23 of 44 (52.3%)	Not reported
Bimatoprost Ophthalmic Solution 0.03%	0 of 41 (0%)	29 of 41 (70.7%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 18 Oct 2013.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Glaucoma, Open-Angle

RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Recruiting
The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).
Glaucoma Open-Angle Primary, Hypertension
RecruitingPhase 4
Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Open Angle Glaucoma (OAG), Glaucoma
RecruitingObservational study
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
Primary Open Angle Glaucoma
Active, not recruitingObservational study
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Primary Open Angle Glaucoma

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Medical Director study director

Allergan

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Oct 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 18 Oct 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Average Eye Intraocular Pressure (IOP) (time frame: Baseline, Day 29 Hour 0). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01001195.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2013.